Published in Clin Cancer Res on December 15, 2007
Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma | NCT00942747
PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res (2009) 2.32
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer (2008) 1.37
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol (2011) 1.14
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One (2011) 1.12
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol (2014) 1.06
Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol (2015) 0.98
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol (2009) 0.98
Inhibitors of mTOR. Oncologist (2010) 0.95
mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation. Oncogene (2015) 0.95
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther (2011) 0.90
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Invest New Drugs (2011) 0.88
Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr (2012) 0.87
Temsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression. PLoS One (2014) 0.81
GPCRs in stem cell function. Prog Mol Biol Transl Sci (2013) 0.80
Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One (2011) 0.80
In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways. Int J Mol Sci (2014) 0.78
A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent. J Neurooncol (2014) 0.76
Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle (2015) 0.75
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. Cancer Cell Int (2016) 0.75
Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations. J Neurooncol (2017) 0.75
Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus. PLoS One (2017) 0.75
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol (2004) 3.40
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs (2005) 2.30
Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res (2002) 1.76
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res (2006) 1.75
Pten signaling in gliomas. Neuro Oncol (2002) 1.62
Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther (2005) 1.32
Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs (2006) 1.25
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs (2004) 1.23
PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med (2001) 1.21
In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos (2007) 0.92
Is it important to correct apparent drug tissue concentrations for blood contamination in the dog? Fundam Clin Pharmacol (2004) 0.89
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2009) 6.11
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol (2009) 5.75
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys (2007) 5.07
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol (2006) 4.88
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2011) 4.12
Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol (2008) 4.11
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol (2012) 3.96
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2005) 3.50
Inequality in early childhood: risk and protective factors for early child development. Lancet (2011) 3.48
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res (2003) 3.36
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol (2004) 3.25
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Targeted molecular therapy of GBM. Brain Pathol (2003) 3.02
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Malignant spinal-cord compression. Lancet Oncol (2005) 2.71
MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol (2005) 2.70
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol (2003) 2.63
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology (2003) 2.61
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A (2009) 2.55
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol (2014) 2.42
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res (2010) 2.41
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol (2012) 2.39
Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther (2003) 2.38